Authors: Emmie de Wit, Brandi N. Williamson, Friederike Feldmann, Kerry Goldin, Michael K. Lo, Atsushi Okumura, Jamie Lovaglio, Elaine Bunyan, Danielle P. Porter, Tomas Cihlar, Greg Saturday, Christina F. Spiropoulou, Heinz Feldmann
Year: 2024
Journal: Antiviral Res.
DOI: 10.1016/j.antiviral.2023.105658
Summary#
Late treatment with remdesivir partially protects African green monkeys from lethal Nipah virus infection, but does not prevent clinical disease or histologic lesions in the brain.
Key Findings#
- Remdesivir treatment provided partial protection for African green monkeys when initiated 3 days post-infection
- 67% of high dose group survived the challenge, but surviving animals showed brain lesions
- Early administration is critical for effective remdesivir treatment during Nipah virus infection
Methodology#
- Study Type: Experimental Study
- Sample Size: 6 African green monkeys per group
- Geographic Focus: Hamilton, MT, United States of America
- Time Period: Unknown
Topics#
Nipah Virus, Antiviral, Remdesivir, Nonhuman Primates
Relevance#
These findings suggest that remdesivir may be effective in treating Nipah virus infection, but early administration is crucial for optimal results.